Methodological considerations on the network meta-analysis of brexpiprazole dosing for agitation in Alzheimer's disease

Abstract

Get full access to this article

View all access options for this article.

References

Kandeel

Mahmoud

. Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer’s disease: a systematic review and network meta-analysis. J Alzheimers Dis 2025; 109: 1089–1098.

Higgins

JPT

Thomas

Chandler

, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 (updated February 2021). London: Cochrane, 2021.

Hutton

Salanti

Caldwell

, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–784.

Marinheiro

Dantas

Mutarelli

, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s disease: a meta-analysis of randomized controlled trials. Neurol Sci 2024; 45: 4679–4686.

da Silva

AMP

Falcão

Gonçalves

, et al. Brexpiprazole for the treatment of agitation in older adults with Alzheimer’s disease: a systematic review, Bayesian meta-analysis, and meta-regression. CNS Drugs 2025; 39: 1071–1082.